INTERNATIONAL FEDERATION OF RED CROSS (IFRC)
In 2007, the World Health Organization (WHO) Pyongyang office and PyongSu Pharma worked together to guarantee the manufacturing plant was compliant with international standards in Good Manufacturing Practices. With the support of international consultants and industry experts, PyongSu Pharma successfully complied and thus became an eligible supplier for the International Federation of Red Cross (IFRC), allowed to participate in international tenders for the North Korean market only.
PyongSu would manufacture up to 3,000 kits, each containing the following items:
|1||Acetyl-salicylic acid 300mg tab||1000 tabs||4|
|2||Paracetamol 500mg tab||1000 tabs||3|
|3||Paracetamol 100mg tab||1000 tabs||4|
|4||Cotrimoxazole 480mg tab||1000 tabs||2|
|5||Cotrimoxazole 120mg tab||1000 tabs||4|
|6||Metronidazole 250mg tab||500 tabs||2|
|7||Mebendazole 500mg tab||100 tabs||1|
|8||Salbutamol 4mg||500 tabs||2|
|9||Zinc Sulphate 20mg dispersible tab||10 tabs||100|
WORLD HEALTH ORGANISATION (WHO)
It was thanks to the WHO Pyongyang office, headed by Dr. Tej Walia, that PyongSu Pharma became Good Manufacturing Practice compliant and thereafter eligible to bid against international manufacturers to supply essential medicines to the IFRC.
WHO also ordered from PyongSu on 2 separate occasions: Albendazole 400mg tablets and Propranolol 20mg tablets.